Drugs
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
Drugs
May 12, 2024, 07:27 |
Drugs
Tanja Obradovic summarizes the latest news on immunotherapy with chemoradiation NSCLC
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared on LinkedIn: “Based on what…
May 11, 2024, 11:58 |
Drugs
David Fajgenbaum: How is the price of a drug
David Fajgenbaum, Associate Professor of Medicine at University of Pennsylvania School of Medicine, shared on X:…
May 10, 2024, 17:49 |
Drugs
Piotr Wysocki: Relatlimab does not improve the activity of nivolumab plus chemotherapy
Piotr Wysocki recently posted on LinkedIn: "RELATIVITY-060 was an open-label phase II study investigating the…
May 10, 2024, 15:41 |
Drugs
Noubar Afeyan: Our partnership with Novo Nordisk brings together the best of two companies in drug development
Noubar Afeyan, Founder and CEO of Flagship Pioneering, shared a post by Flagship Pioneering on…
May 8, 2024, 13:20 |
Drugs
CDK4 inhibitor on the horizon - Oncology Experts
Oncology Experts shared on LinkedIn: "PF-07220060, another CDK4 inhibitor on the horizon. Reported by Pfizer…
May 8, 2024, 01:20 |
Drugs
Talha Badar: Myelofibrosis after failure of Ruxolitinib
Talha Badar, Assistant Professor at Mayo Clinic Comprehensive Cancer Center shared a thread on Twitter/X:…
May 2, 2024, 02:53 |
Drugs
FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years and older with GEP-NETS
FDA Approves the First Radioactive Drug for Pediatric Neuroendocrine Tumors the U.S. Food and Drug…
May 1, 2024, 17:21 |
Drugs
Piotr Wysocki: Adjuvant aspirin failed to improve outcomes of breast cancer patients
Piotr Wysocki recently shared on LinkedIn: "A large, phase III trial (Alliance A011502) enrolled 3020…
May 1, 2024, 09:57 |
Drugs
Tanja Obradovic: Dostarlimab chemotherapy in primary advanced or recurrent endometrial cancer
Tanja Obradovic, Vice President, Oncology Scientific Affairs at ICON, shared on LinkedIn: "Further inroads of…
Apr 29, 2024, 14:18 |
Drugs
Matthew Goetz: Abemacicib in high risk ER+/HER2 negative breast cancer
Matthew Goetz, Professor of Oncology and Pharmacology at Mayo Clinic, shared on LinkedIn: “An important…
1
2
3
4
5
All:
305
Posts:
11 - 20
OncoInfluencers: Dialogue with Rob Pieters, hosted by Shushan Hovsepyan
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Facebook
RSS Feed
Twitter
Linkedin
Youtube